- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12. | Fractyl Health, Inc.: Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular ... | 2 | GlobeNewswire (USA) | ||
| 09.12. | Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | 1 | GlobeNewswire (USA) | ||
| 12.11. | Fractyl Health reports Q3 resultsa | 1 | Seeking Alpha | ||
| FRACTYL HEALTH Aktie jetzt für 0€ handeln | |||||
| 12.11. | Fractyl Health, Inc.: Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | 135 | GlobeNewswire (Europe) | REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024... ► Artikel lesen | |
| 04.11. | Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 04.11. | Fractyl Health, Inc.: Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 | 136 | GlobeNewswire (Europe) | Single Revita procedure led to sustained, clinically meaningful weight loss in majority of patients with Type 2 Diabetes REMAIN-1 weight maintenance pivotal study on-track to report mid-point data... ► Artikel lesen | |
| 29.10. | Fractyl Health, Inc.: Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 | 1 | GlobeNewswire (USA) | ||
| 28.10. | Fractyl Health, Inc.: Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 24.09. | Fractyl Health, Inc.: Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference | 1 | GlobeNewswire (USA) | ||
| 14.09. | Fractyl Health president sells over $188k in company stock | 14 | Investing.com | ||
| 03.09. | Fractyl Health, Inc.: Fractyl Health to Participate in Upcoming September Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 14.08. | Fractyl Health, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 07.08. | Fractyl Health, Inc.: Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 | 1 | GlobeNewswire (USA) | ||
| 30.07. | Fractyl gets FDA breakthrough device status for Revita | 1 | Seeking Alpha | ||
| 30.07. | Fractyl Health, Inc.: Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs | 90 | GlobeNewswire (Europe) | Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or... ► Artikel lesen | |
| 30.07. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Fractyl Health, Inc.: Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 | 194 | GlobeNewswire (Europe) | Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein... ► Artikel lesen | |
| 13.05. | Fractyl Health, Inc.: Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates | 710 | GlobeNewswire (Europe) | Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal... ► Artikel lesen | |
| 13.05. | Fractyl Health, Inc.: Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) | 112 | GlobeNewswire (Europe) | First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita... ► Artikel lesen | |
| 02.04. | Fractyl Health, Inc.: Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes | 131 | GlobeNewswire (Europe) | BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,90 | -0,27 % | AT&S, BioNTech, Deutsche Bank, Kontron, Manz, Süss Microtec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CUREVAC | 2,852 | -0,28 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| AMGEN | 254,15 | +0,20 % | Spotlight on Amgen: Analyzing the Surge in Options Activity | ||
| NOVAVAX | 8,242 | -0,79 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| BIOGEN | 143,80 | +0,17 % | BMO cuts rating on Merck and Biogen, on lack of near term catalyst | ||
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Vereinbarung mit Quest Diagnostics über die Bereitstellung von Labor-Services im Rahmen der klinischen Studie für den Darmkrebsfrüherkennungstest bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed gibt Vereinbarung mit Quest Diagnostics über die Bereitstellung von Labor-Services im Rahmen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,700 | +0,60 % | Peering Into Intellia Therapeutics' Recent Short Interest | ||
| VIKING THERAPEUTICS | 40,730 | +0,17 % | AKTIEN IM FOKUS: Novo Nordisk sacken nach Daten ab - Gerresheimer schwach | KOPENHAGEN/FRANKFURT/NEW YORK (dpa-AFX) - Enttäuschende Studienergebnisse haben dem dänischen Pharmakonzern Novo Nordisk am Freitag den höchsten Kursverlust in seiner Geschichte eingebrockt. Die Papiere... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,430 | -0,70 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,212 | +0,83 % | Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases 18,900 Shares of Stock | ||
| EXELIXIS | 31,850 | -0,99 % | Brookline Capital setzt 40 US-Dollar Kursziel für Exelixis-Aktie mit Kaufempfehlung | ||
| SAREPTA THERAPEUTICS | 115,10 | -0,69 % | Sarepta awarded $115.2M in Vyondys 53 patent case: report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,829 | -1,15 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
| VAXART | 0,571 | -1,89 % | Vaxart, Inc.: Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's... ► Artikel lesen | |
| EXACT SCIENCES | 56,25 | -0,78 % | Exact Sciences Corp.: Exact Sciences Advances Breast Cancer Care with the Oncotype DX test and Genomic Profiling Research at SABCS 2024 | New data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally
Exact Sciences... ► Artikel lesen |
Das Unternehmen FRACTYL HEALTH INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,895 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FRACTYL HEALTH INC finden Sie auf Wallstreet Online.
